The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and DesignDerek C. Angus, Steven Webb, Srinivas Murthy et al.|Annals of the American Thoracic Society|2020Cited by 449
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term OutcomesKristine Broglio, Donald A. Berry, Melanie Quintana et al.|JAMA Oncology|2016Cited by 375
Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With SepsisJonathan Sevransky, Ithan D. Peltan, Richard E. Rothman et al.|JAMA|2021Cited by 277
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary reportChristopher W. Seymour, Anthony Gordon, Paul Mouncey et al.|medRxiv|2021Cited by 137
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trialYaseen M. Arabi, Anthony Gordon, Lennie Derde et al.|Intensive Care Medicine|2021Cited by 100